Surfactant Protein D Levels in Covid-19 Infection: Case-Control Study

Covid19 Clinical Trial

Official title: Surfactant Protein D Levels in Covid-19 Infection: Case-Control Study

Status Completed

Clinical Trial Summary

This study aims to provide some insight into the variation of SD-D protein levels in patients with Covid-19 (-) pneumonia, Covid-19 (+) pneumonia, and CT negative Covid-19 infection in comparison to the normal population through a larger number of cases. Objective of the study is to determine the serum surfactant protein D (SP-D) levels in Covid-19 pneumonia infection.

Clinical Trial Description

This study aims to provide some insight into the variation of SD-D protein levels in patients with Covid-19 (-) pneumonia, Covid-19 (+) pneumonia, and CT negative Covid-19 infection in comparison to the normal population through a larger number of cases. Subjects will assessed in accordance with the inclusion and exclusion criteria, they were divided into four groups as the CT (-), PCR (+) SARS-CoV-2 infection group, SARS-CoV-2 (+) Pneumonia Group, CT (+), PCR (-) Suspected Pneumonia Group and Healthy group (Control Group). Demographic data, medical history, vital findings (fever, blood pressure, sPO2), laboratory findings (complete blood count; C-reactive protein (CRP), D-dimer, Ferritin and hsTnT parameters) and radiological findings, time to onset of symptoms, Comorbid diseases, hospitalization location of the patients (service or ICU), clinical scores, CT severity scores will determine. SP-D level will analyze by the Enzyme-Linked Immunosorbent Assay (ELISA) method. ;

Related Conditions & MeSH terms

• Covid19
• Infection
• Pneumonia
• Protein Deficiency
• Surfactant Protein Deficiency

• NCT number: NCT04618861
• Study type: Observational
• Source: Kafkas University
• Status: Completed
• Start date: October 13, 2020
• Completion date: November 2, 2020